Images List Premium Download Classic

Antagonist

Antagonist-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Genetically encoded calcium indicators and methods of use
Howard Hughes Medical Institute
October 12, 2017 - N°20170292943

Genetically encoded calcium indicator (geci) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of g-protein coupled receptor (gpcr) or ion channels and methods of monitoring neural activity also are provided.
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
Novartis Ag
October 12, 2017 - N°20170291939

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a and a peptide tag that binds hyaluronan (ha). The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17...
Fluorinated integrin antagonists
Scifluor Life Sciences, Inc.
October 12, 2017 - N°20170291900

The present invention relates to fluorinated compounds of formula i and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (dr), macular edema, diabetic macular edema (dme), and macular edema following retinal vein occlusion (rvo), by administering these compounds and pharmaceutical ...
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
Genentech, Inc.
October 12, 2017 - N°20170290913

The invention provides compositions and methods for treating cancers. The method comprises administering a pd-1 axis binding antagonist and an ox40 binding agonist.
Compositions and methods for treating inflammatory conditions of the ocular surface
The Schepens Eye Research Institute, Inc.
October 12, 2017 - N°20170290888

This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more c-c chemokine receptor type 7 (ccr7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.
Methods of treating prostate cancer with gnrh antagonist
Ferring B.v.
October 12, 2017 - N°20170290879

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (gnrh) antagonist without causing a testosterone spike and/or other side effect of gnrh agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel compounds alpha v beta 6 integrin antagonists
Versi Group, Llc
October 12, 2017 - N°20170290818

Wherein r1 is hydrogen, cyclopropyl, or pyrazolyl, wherein said pyrazolyl is optionally substituted by one or two methyl groups; or a pharmaceutically acceptable salt thereof.
Novel compounds alpha v beta 6 integrin antagonists
Versi Group, Llc
October 12, 2017 - N°20170290817

Which is 4-(3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid, or a salt thereof.
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
Chemocentryx, Inc.
October 12, 2017 - N°20170290808

The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a pd-l1 inhibitor or a pd-1 inhibitor in combination with a small molecule chemokine ...
Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract
Servicio Andaluz De Salud
October 12, 2017 - N°20170290774

The present invention relates to a composition comprising a neurokinin-1 receptor antagonist and at least one excipient selected from an oil, a fatty acid or a polyol, as well as to an administration form for administering a formulation, wherein said administration form is selected from: inhalant, nebulization, vapor, smoke or aerosol and comprises said composition. In addition, the invention relates ...
Compositions comprising bile acid sequestrants for treating esophageal disorders
Ironwood Pharmaceuticals, Inc.
October 12, 2017 - N°20170290767

Disclosed herein are novel compositions and methods for treating or preventing upper gi tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one ...
Screening methods for thyroid hormone disruptors based on co-regulator involved simulations
Nanjing University
October 05, 2017 - N°20170285007

The present patent relates to a method for qualitative identification and quantitative prediction of thyroid hormone disrupting chemicals base on the interaction between thyroid hormone receptor and co-regulators (coactivator and corepressor). The method identifies chemicals as passive antagonists, active antagonists and agonists by means of co-regulator involved molecular dynamics simulations, and predicts the relative disrupting potencies by use of binding ...
Rac1 inhibitors for the treatment of alport glomerular disease
Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital
October 05, 2017 - N°20170285005

The present invention provides methods of treating alport syndrome in a subject by the administration of an agent that blocks the activation of rac1/cdc42 members of the rho family of small gtpases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1. Such administration prevents invasion of ...
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Human beta-adrenergic receptor kinase polypeptide and methods
Incyte Corporation
October 05, 2017 - N°20170283783

Various embodiments of the invention provide human kinases and phosphatases (kpp) polypeptides and polynucleotides which identify and encode kpp. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of kpp.
Compositions comprising rank/rankl antagonists and related compounds for treating pain
Antecip Bioventures Ii Llc
October 05, 2017 - N°20170283503

Disclosed herein are methods of treating pain using rank/rankl antagonists.
Human anti-il-33 neutralizing monoclonal antibody
Mitsubishi Tanabe Pharma Corporation
October 05, 2017 - N°20170283494

An antibody has an antagonistic effect against il-33. In particular an isolated human anti-il-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-il-33 monoclonal antibodies were identified, human anti-il-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ...
Soluble c5ar antagonists
Mitsubishi Tanabe Pharma Corporation
October 05, 2017 - N°20170283446

Including stereoisomers and pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Nk1 antagonists
Mitsubishi Tanabe Pharma Corporation
October 05, 2017 - N°20170283434

Wherein ar1 and ar2 are optionally substituted phenyl or heteroaryl, x1 is an ether, thio or imino linkage, r4 and r5 are not both h or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents ...
Substituted thiazole or oxazole p2x7 receptor antagonists
Mitsubishi Tanabe Pharma Corporation
October 05, 2017 - N°20170283409

The compounds are useful in the treatment or prophylaxis of diseases associated with p2x7 receptor activity in animals, in particular humans.
Method of treating patients non-responsive to palonosetron
Heron Therapeutics, Inc.
October 05, 2017 - N°20170281779

A method for treating chemotherapy-induced nausea and vomiting in individuals undergoing chemotherapy and previously treated with, and whom failed to respond to, a 5-ht3 antagonist other than granisetron is described. Individuals who fail to respond to, for example, palonosetron, as evidenced by an inadequate prevention or attenuation of acute or delayed chemotherapy-induced nausea and vomiting, are treated with a semi-solid ...
Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
Heron Therapeutics, Inc.
October 05, 2017 - N°20170281762

The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (psa) patients using il-17 antagonists, e. G., il-17 antibodies and antigen-binding fragments thereof, e. G., secukinumab.
Loading